Trial Outcomes & Findings for EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer (NCT NCT05086705)

NCT ID: NCT05086705

Last Updated: 2025-04-22

Results Overview

Feasibility will be evaluated primarily with respect to device usage. The proportion of patients who wear the device for at least 8 hours between 8:00 am and 8:00 pm for at least 22 days will be estimated using the entire sample and a 95% Jeffreys interval for binomial proportions will be computed.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

50 participants

Primary outcome timeframe

Up to 8 weeks

Results posted on

2025-04-22

Participant Flow

Participant milestones

Participant milestones
Measure
Arm A (EMBr Wave First)
Patients utilize the EMBr Wave device for 4 weeks, then receive no treatment for 4 weeks. EMBr Wave: Use EMBr Wave Questionnaire Administration: Ancillary studies
Arm B (EMBr Wave Second)
Patients receive no treatment for 4 weeks, then utilize the EMBr Wave Device for 4 weeks. EMBr Wave: Use EMBr Wave Questionnaire Administration: Ancillary studies
Overall Study
STARTED
25
25
Overall Study
COMPLETED
25
25
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Arm A (EMBr Wave First)
n=25 Participants
Patients utilize the EMBr Wave device for 4 weeks, then receive no treatment for 4 weeks. EMBr Wave: Use EMBr Wave Questionnaire Administration: Ancillary studies
Arm B (EMBr Wave Second)
n=25 Participants
Patients receive no treatment for 4 weeks, then utilize the EMBr Wave device for 4 weeks. EMBr Wave: Use EMBr Wave Questionnaire Administration: Ancillary studies
Total
n=50 Participants
Total of all reporting groups
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
23 Participants
n=99 Participants
25 Participants
n=107 Participants
48 Participants
n=206 Participants
Age, Categorical
>=65 years
2 Participants
n=99 Participants
0 Participants
n=107 Participants
2 Participants
n=206 Participants
Sex: Female, Male
Female
25 Participants
n=99 Participants
25 Participants
n=107 Participants
50 Participants
n=206 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
25 Participants
n=99 Participants
25 Participants
n=107 Participants
50 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=99 Participants
2 Participants
n=107 Participants
5 Participants
n=206 Participants
Race (NIH/OMB)
White
22 Participants
n=99 Participants
23 Participants
n=107 Participants
45 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
25 participants
n=99 Participants
25 participants
n=107 Participants
50 participants
n=206 Participants

PRIMARY outcome

Timeframe: Up to 8 weeks

Population: Data was not collected or analyzed

Feasibility will be evaluated primarily with respect to device usage. The proportion of patients who wear the device for at least 8 hours between 8:00 am and 8:00 pm for at least 22 days will be estimated using the entire sample and a 95% Jeffreys interval for binomial proportions will be computed.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: At 8 weeks

Population: Patient satisfaction data was only obtained for the 29 out of 50 participants who gave responses for the exit survey (12 from Arm A and 17 from Arm B). Satisfaction scores pertain to satisfaction with EMBr wave device usage, so no data is reported for the No Treatment Group

Feasibility will be evaluated secondarily with respect to patient satisfaction. The mean patient satisfaction scores for each Likert-type question and proportion of patients reporting satisfaction scores at or above 7 will be estimated in the entire sample and compared between sequence groups at the 5% significance level (two-sided).Rated on a 10-point Likert scale with 10 being most satisfied or most effective.

Outcome measures

Outcome measures
Measure
EMBr Wave Device
n=29 Participants
Participants utilized the EMBr wave device for 4 weeks.
No Treatment
Patients received no treatment for 4 weeks.
Patient Satisfaction
Duration
5.48 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Work
4.76 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Social
4.72 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Leisure
4.86 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Sleep
4.41 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Mood
4.97 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Concentrate
4.90 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Relation
4.41 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Sexuality
3.24 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Enjoy
5.10 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Quality
5.38 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Worth
5.79 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Satisfy
5.52 score on a scale
Interval 0.0 to 10.0
Patient Satisfaction
Intensity
4.97 score on a scale
Interval 0.0 to 10.0

SECONDARY outcome

Timeframe: At week 4 and at week 8

Reported via patient reported outcomes, primarily Hot Flash-Related Daily Interference Scale (HFRDIS), a scale of 0-10 with 0 being no interference (best outcome) and 10 being completely interfere (worst outcome). Survey administered on paper or via RedCap survey distribution at week 4 and week 8.

Outcome measures

Outcome measures
Measure
EMBr Wave Device
n=50 Participants
Participants utilized the EMBr wave device for 4 weeks.
No Treatment
n=50 Participants
Patients received no treatment for 4 weeks.
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Enjoyment of Life
3.2259 units on a scale
Standard Error 0.3234
3.3231 units on a scale
Standard Error 0.3651
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Work
3.6368 units on a scale
Standard Error 0.3386
3.6743 units on a scale
Standard Error 0.3261
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Social Activities
3.0626 units on a scale
Standard Error 0.3356
3.1652 units on a scale
Standard Error 0.3590
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Leisure Activities
3.4362 units on a scale
Standard Error 0.3063
3.5256 units on a scale
Standard Error 0.3566
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Sleep
4.8231 units on a scale
Standard Error 0.3948
5.4950 units on a scale
Standard Error 0.3403
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Mood
3.7743 units on a scale
Standard Error 0.3367
4.0794 units on a scale
Standard Error 0.3254
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Concentration
3.7391 units on a scale
Standard Error 0.3464
4.1341 units on a scale
Standard Error 0.3634
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Relations with others
2.5774 units on a scale
Standard Error 0.3331
2.6717 units on a scale
Standard Error 0.3520
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Sexuality
2.9739 units on a scale
Standard Error 0.4058
3.1144 units on a scale
Standard Error 0.4228
Effect of EMBr Wave Using Hot Flash-Related Daily Interference Scale (HFRDIS)
Quality of Life
3.4489 units on a scale
Standard Error 0.3248
3.5543 units on a scale
Standard Error 0.3386

Adverse Events

EMBr Wave Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

No Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Sagar Sardesai

The Ohio State University Comprehensive Cancer Center

Phone: 614-293-6401

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place